Robins Kaplan LLP Named a Recommended Firm for Hatch-Waxman by LMG Life Sciences

December 1, 2016

Robins Kaplan LLP is pleased to announce that LMG Life Sciences has recommended the firm as a top Hatch-Waxman patent litigation firm for generic pharmaceutical companies. LMG Life Sciences also named two members of Robins Kaplan’s Hatch-Waxman Litigation practice group “Life Science Stars.” Recipients include:

The recognition is a reflection of the firm’s successful representation of generic pharmaceutical companies, as well as the sophisticated legal and scientific understanding of the attorneys who practice in the field. Recipients were chosen based on nearly 1,000 interviews and surveys, including firm-wide surveys, interviews with individual attorneys and clients, and a review of public information.

Jake M. Holdreith

Partner

Member of Executive Board

Ronald J. Schutz

Partner

Chair of Executive Board

Related Publications

Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top